The Food and Drug Administration’s approval of lecanemab, a new Alzheimer’s medication shown in clinical trials to reduce the disease slowly over time.
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
The Food and Drug Administration’s approval of lecanemab, a new Alzheimer’s medication shown in clinical trials to reduce the disease slowly over time.
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio